Ronald B. Moss
Direktor/Vorstandsmitglied bei Biosortia Pharmaceuticals, Inc.
Vermögen: 104 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ross O. Youngs | M | - |
Biosortia Pharmaceuticals, Inc.
 Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | 16 Jahre |
| Howard Birndorf | M | 74 | 5 Jahre | |
| Peter Wendell | M | 73 | 21 Jahre | |
| David R. Coho | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| Vickie Reed | F | 62 | 2 Jahre | |
| Meera Desai | M | 45 | 3 Jahre | |
| John A. Ryals | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| Henry Joseph Cialone | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| James Matteucci | M | - | 21 Jahre | |
| Douglas Poling | M | - |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
| Derrell Porter | M | 53 |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Dennis J. Carlo | M | 80 |
Telos Pharmaceuticals LLC
Orchestra Therapeutics, Inc.
 Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 34 Jahre |
| Richard Kogan | M | 81 | 21 Jahre | |
| Fred Hassan | M | 78 | 6 Jahre | |
| Robert O. Hopkins | M | 63 | 14 Jahre | |
| Roshawn Blunt | F | 49 | 2 Jahre | |
| Jeffrey Sachs | M | - |
Stony Brook University
| 8 Jahre |
| Mark Flather | M | - | 8 Jahre | |
| Ismail Kola | M | 67 | 4 Jahre | |
| David Anstice | M | 75 | 5 Jahre | |
| William C. Denby | M | 69 | 5 Jahre | |
| Robert B. Rothermel | M | 80 | 5 Jahre | |
| John N. Bonfiglio | M | 69 |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 2 Jahre |
| Larry W. Granatelli | M | - |
Stony Brook University
| 6 Jahre |
| Simon D. Kelner | M | 51 | 13 Jahre | |
| Rosemary Dehlow | F | - |
Stony Brook University
| 4 Jahre |
| Eduardo O. Thompson | M | - | 6 Jahre | |
| Bruce A. Deitchman | M | - |
Stony Brook University
| 4 Jahre |
| David Feinberg | M | 61 |
Chicago Medical School
| 4 Jahre |
| Bing Chan | F | - |
Stony Brook University
| 4 Jahre |
| Robert W. Verdugo | M | - | 3 Jahre | |
| Manal Morsy | M | - | 9 Jahre | |
| Andrew R. de Guttadauro | M | 57 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | 3 Jahre |
| Sheldon R. Reich | M | 66 |
Stony Brook University
| 3 Jahre |
| Jane Anne Salik | M | 71 |
Stony Brook University
| 3 Jahre |
| Egil Bodd | M | 69 | 11 Jahre | |
| Pradeep K. Wahi | M | - |
Stony Brook University
| 4 Jahre |
| Mitch L. Levin | M | - |
Stony Brook University
| 4 Jahre |
| Dalei Shao | M | - | 2 Jahre | |
| Joseph H. McKenna | M | - |
Stony Brook University
| 4 Jahre |
| Pieter H. Smit | M | - |
Stony Brook University
| 4 Jahre |
| Eric Greenspan | M | - |
Stony Brook University
| 5 Jahre |
| Yaacov Weinstock | M | - | 1 Jahre | |
| Michael James Cash | M | - |
Stony Brook University
| 3 Jahre |
| Michael Foley | M | 66 |
Chicago Medical School
| 4 Jahre |
| David Ege | M | 50 | 16 Jahre | |
| Gary Goldman | M | - |
Stony Brook University
| 4 Jahre |
| Judith C. Seltz | F | 61 | 15 Jahre | |
| Robert Hansen | M | - |
Stony Brook University
| 3 Jahre |
| Bob Moore | M | - |
Stony Brook University
| 2 Jahre |
| Kenneth Peter Steinmetz | M | - |
Stony Brook University
| 4 Jahre |
| Richard Napolitano | M | - |
Stony Brook University
| 5 Jahre |
| Nancy Thornberry | F | 67 | 9 Jahre | |
| Corey S. Kupfer | M | - |
Stony Brook University
| 4 Jahre |
| Hüseyin Bayazit | M | 65 |
Stony Brook University
| 4 Jahre |
| John Yates | M | 67 | 13 Jahre | |
| Mustaque Ahamad | M | - |
Stony Brook University
| 3 Jahre |
| Paul Marcotrigiano | M | - |
Stony Brook University
| 4 Jahre |
| Richard E. Aiello | M | - |
Stony Brook University
| 4 Jahre |
| Gerald L. Wisler | M | 67 | 20 Jahre | |
| Wendy Perrow | F | 66 | 14 Jahre | |
| James Christopher Scalet | M | 65 | 9 Jahre | |
| George P. Vlasuk | M | - |
Stony Brook University
| 2 Jahre |
| Martyn Greenacre | M | 82 |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 5 Jahre |
| Emmanuel Lakios | M | 62 |
Stony Brook University
| 4 Jahre |
| Mark A. Burnett | M | 64 |
Stony Brook University
| 4 Jahre |
| Richard M. Bartholomew | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | - |
| Peter Lowry | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | - |
| Mark A. Varney | M | 57 | 4 Jahre | |
| Willie Deese | M | 68 | 12 Jahre | |
| William Daley | M | 75 | 4 Jahre | |
| Rahul Singhvi | M | 59 | 5 Jahre | |
| Patrick Yang | M | 75 | 11 Jahre | |
| Young C. McGuinn | F | 64 | 6 Jahre | |
| David Arkowitz | M | 62 | 3 Jahre | |
| Stephen Gold | M | 65 | 2 Jahre | |
| Paul Howes | M | 69 | 5 Jahre | |
| Gregory Butler | M | 66 |
Stony Brook University
| 4 Jahre |
| Jeffrey Lightcap | M | 66 |
Stony Brook University
| 4 Jahre |
| Glenn Dubin | M | 67 |
Stony Brook University
| - |
| Steven Richieri | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 8 Jahre |
| Steven Nichtberger | M | 62 | 8 Jahre | |
| Russell B. Brown | M | - |
Stony Brook University
| 4 Jahre |
| Bill Hayde | M | 59 |
Stony Brook University
| 4 Jahre |
| Christopher Duffy | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 12 Jahre |
| Cono A. Carrano | M | - |
Stony Brook University
| 4 Jahre |
| Howard Chin | M | - | 1 Jahre | |
| Thomas Martin Vernon | M | 85 | - | |
| Bernard J. Kelley | M | 82 | 10 Jahre | |
| Wai Lam | M | - |
Stony Brook University
| 4 Jahre |
| Alan S. Rosenthal | M | - |
Orchestra Therapeutics, Inc.
Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | 6 Jahre |
| David King | M | 65 |
Stony Brook University
| 2 Jahre |
| David H. Langsam | M | - |
Stony Brook University
| 4 Jahre |
| Steven I. Traum | M | - |
Stony Brook University
| 4 Jahre |
| Linda Burns | F | - | 1 Jahre | |
| Guy MacDonald | M | 65 | 22 Jahre | |
| Ben Shapiro | M | 84 | 13 Jahre | |
| Joseph C. Zinghini | M | - |
Stony Brook University
| 4 Jahre |
| Ihab Labib Salib | M | - |
Stony Brook University
| 4 Jahre |
| Joe Rosen | M | - |
Stony Brook University
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Ronald B. Moss
- Persönliches Netzwerk
